Specific Molecular Patterns Could be a Strong Marker for ALS Progression and Prognosis, Study Contends

Specific Molecular Patterns Could be a Strong Marker for ALS Progression and Prognosis, Study Contends

The patterns of methylation in arginine residues circulating in the cerebrospinal fluid — the liquid that circulates in the brain and spinal cord — could be a strong indicator of disease progression and prognosis among patients with amyotrophic lateral sclerosis (ALS).

The study, “Increase of arginine dimethylation correlates with the progression and prognosis of ALS,” was published in Neurology.

Arginine, also known as L-arginine, is one of the essential amino acids (the building blocks of proteins) in our body.

Arginine methylation — the adding of small chemical methyl groups to arginine — is one of the most common chemical modifications that occur in proteins that interact with RNA molecules and help regulate gene expression,  the so-called RNA-binding proteins. (RNA is the template for the production of a protein.)

Arginine methylation is driven by a family of enzymes called protein arginine methyltransferases (PRMTs). Of these, PRMT1 is by far the most common,  accounting for more than 90% of the total production of methylated L-arginine, which also is known as asymmetric dimethyl L-arginine (ADMA).

“The major substrates [targets] of PRMT1 are RNA-binding proteins such as hnRNPs, FET proteins (FUS, EWS, and TAT15), and ELAV/Hu proteins, many of which have been shown to be involved in the pathology of motor neuron diseases, [including ALS],” the investigators wrote.

Discuss the latest research in the ALS News Today forums!

In this study, a group of Japanese researchers set out to investigate if the methylation pattern of arginine driven by PRMT1 is altered in ALS patients and how it correlates with disease progression, severity and prognosis.

Researchers measured the levels of total L-arginine, as well as methylated arginine residues, in CSF samples from 52 patients with ALS and 21 patients with other neurological disorders (controls), such as Parkinson’s disease, multiple system atrophy, chronic inflammatory demyelinating polyneuropathy and multiple sclerosis, among others, using a technique called liquid chromatography–tandem mass spectrometry.

Correlation analysis was used to look for potential relationships between the levels of methylated arginine residues and ALS progression, severity and prognosis.

In addition, investigators also performed immunohistochemistry — a technique that allows researchers to visualize specific proteins of interest using specific antibodies that recognize them — to compare the levels of PRMT1 and its products (e.g., asymmetric dimethylated proteins, or ASYM) in post-mortem spinal cord samples from four ALS patients and four patients with other disorders.

Results showed the levels of PRMT1 and ASYM were increased significantly in spinal cord samples from ALS patients, compared to disease controls. Moreover, the levels of ADMA in CSF samples from ALS patients were substantially higher compared to controls.

Correlation analysis demonstrated the ratio of ADMA and non-methylated L-arginine was linked to significant functional declines in scores of the ALS Functional Rating Scale (ALSFRS) measured one year after the the time of measurement.

In addition, a high ADMA/L-arginine ratio was associated with poor ALS prognosis, even in a group of patients whose forced vital capacity (FVC) values were within a normal range.

“[W]e found that the ADMA/L-arginine ratio is a potent predictor of survival and functional decline in patients with ALS. Although we still need to identify the [mechanisms] by which the increased ADMA/L-arginine ratio affects disease progression, it is possible that dysregulation of the ADMA/L-arginine ratio can be a novel therapeutic target for ALS,” the scientists concluded.

Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.
×
Joana is currently completing her PhD in Biomedicine and Clinical Research at Universidade de Lisboa. She also holds a BSc in Biology and an MSc in Evolutionary and Developmental Biology from Universidade de Lisboa. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that make up the lining of blood vessels — found in the umbilical cord of newborns.
Latest Posts
  • ALS progression and weight loss
  • split-hand index
  • SOD1 activity
  • protein clumps and nerve cells

6 comments

  1. Dave Reckonin says:

    “…it is possible that dysregulation of the ADMA/L-arginine ratio can be a novel therapeutic target for ALS,” the scientists concluded.”

    Anyone else think this sounds like …”Give brain tumor patients aspirin for their headaches and when the headache subsides that’s effective therapy for the tumor.”

    I think someone is having a bit of fun with readers.

    • Joana Carvalho says:

      Hi Ardi, not necessarily because L-arginine is not the problem. The problem is that ALS patients tend to have a higher amount of methylated L-arginine because the enzyme that methylates arginine is more active than normal.

      • Bobbie says:

        I have a horse with equine motor neuron disease and im giving high dose vitamin E and will start her on AAKG tomorrow. I hope to see improvement. Its her last hope.

  2. Ed says:

    Or is it quite the opposite? Can you imply from the test results that if the ratio of ADMA/L-arginine is too high, could one then supplement extra L-arginine to improve the ratio and perhaps reduce the neurological decline?

    • Joana Carvalho says:

      Hi Ed, that might help if there is a way to guarantee the extra L-arginine is not being methylated and the ratio of ADMA/L-arginine is not increasing. So in that sense, finding a way to block the excessive activity of PRMT1 in combination with L-arginine supplementation could be a better alternative.

Leave a Comment

Your email address will not be published. Required fields are marked *